Taking advantage of the proximity of bowel mucosa to luminal bacteria, we have attempetd to deliver a therapeutic gene to the colonic mucosa by oral administration of an invasive and non-pathogenic Escherichia coli. E. coli diamenopimelate (dap) auxotroph, harboring plasmid pGB2Oinv-hly, express the inv gene from Yersinia pseudotubercolosis that confers the ability to invade nonprofessional phagocytic cells and the hly gene from Listeria monocytogenes that allows expression of lystreriolysin O, a perforin cytolysin able to perfore phagosomal membranes. This bacterial vector invades and transfers functional DNA to epithelial cells in vitro. We have shown that this strain carrying a therapeutic gene (pC1OTGF-b1) can significantly reduce the severity of experimental colitis in mice. However, as a consequence of mucosal barrier disruption during colitis, vector-specific mRNA transcripts could be recovered from the colon and also from extra-colonic tissues. We therefore replaced the constitutive CMV promoter in pC1OTGF-b1 by the inflammation-inducible interleukin-8 promoter generating plasmid pC1OTGF-b1 IND . Plasmid-specific TGF-b1 mRNA transcripts were detectable in mouse CMT-93 epithelial cells incubated with E. coli BM2710/pGB2Oinv-hly carrying pC1OTGF-b1 IND following exposure to inflammatory cytokines. Furthermore, the transcripts were detectable only within inflamed tissues and the therapeutic effects were comparable to those in animals treated with E. coli BM2710/ pGB2Oinv-hly+pC1OTGF-b1. In summary, engineered enteric bacteria can efficiently deliver in vivo therapeutic genes to the intact intestinal mucosa and regulation expression of the therapeutic gene by an inflammation-inducible promoter prevents its dissemination during colitis.
Introduction
A better understanding of disorders characterized by abnormal activity of the immune system has prompted the development of therapies based on the administration of specific immunomodulatory molecules. 1 Administration of recombinant immunomodulatory cytokines or monoclonal antibodies to neutralize specific inflammatory mediators has been shown to be effective in various inflammatory disorders. 2, 3 Although cytokine-based therapy may represent an attractive therapeutic option for patients unresponsive to traditional treatments, systemic administration of such molecules has several drawbacks: short bioactivity, systemic toxicity, and high cost. 1 Administration of genes coding for immunomodulatory cytokines, aimed at providing therapeutic levels of cytokines produced directly in patient's tissues, gave exciting results in several models of immune-mediated diseases. [4] [5] [6] However, the viral and nonviral gene delivery systems used in these studies have a low efficiency and lack of tissue specificity in vivo results in widespread distribution of the therapeutic gene. 4, 5, 7 Thus, toxic sequels caused by the high circulating levels of immunomodulatory cytokines such as TGF-b1 and IL-10 represent a major obstacle to the development of appealing protocols for transient gene therapies. 8, 9 Several laboratories have recently demonstrated that bacteria can transfer functional genes to a very broad range of eukaryotic cells. 10, 11 Attenuated strains of Shigella, 12 invasive Escherichia coli, 13, 14 Salmonella, 15 and Listeria 16 are able to transfer plasmid DNA to mammalian cells. The bacteria used to transfer genes to phagocytic and nonphagocytic cells are facultative intracellular pathogens that have been designed to lyse after cell invasion. We have used a nonpathogenic, genetically defined invasive strain of E. coli K12 that undergoes lysis upon entry into mammalian cells because of impaired cell wall synthesis due to diaminopimelate (dap) auxotrophy. This strain, E. coli BM2710, has been transformed with a plasmid containing the inv locus encoding the invasin from Yersinia pseudotuberculosis (allowing bacterial entry into nonphagocytic cells expressing b1-integrin) and the hly gene coding for the listeriolysin O from Listeria monocytogenes (allowing bacterial escape from the entry vesicle). 14 Using this E. coli strain, efficient and stable gene transfer is observed after 2-h coincubation of bacteria and various mammalian cell lines in vitro.
Innovative therapies for inflammatory bowel diseases (IBD) should provide selective delivery of immunoregulatory molecules to the site of inflammation. The pathological process in IBD, mainly ulcerative colitis and Crohn's disease, presents the attractive peculiarity to be in direct continuity with the bowel lumen. Topical applications of conventional anti-inflammatory drugs are therefore frequently used to reach therapeutic levels in the colonic mucosa. 1 Since previous studies have shown the possibility to treat chronic inflammatory colitis by transient gene therapy, 4, 5 we have attempted to deliver a therapeutic gene (TGF-b1) to the colonic mucosa by an engineered enteric bacterium. TGF-b1 is an immunomodulatory cytokine able to inhibit macrophage and T-cell activity favoring the release of Th2 over Th1 cytokines. 17 In addition, TGF-b1 mediates tissue homeostasis and restoration, thus uncontrolled inflammatory responses develop in TGF-b1 knockout mice, whereas TGF-b1 administration reverses experimental allergic and inflammatory diseases. 18, 19 We have administered a TGF-b1-coding plasmid since local production of TGF-b1 might contribute to re-establish an equilibrated activity of the mucosal immune system during idiopathic chronic inflammatory disorders while avoiding the onset of systemic undesired effects. 8, 9 Results E. coli BM2710/pGB2Oinv-hly transfers functional genes to colonic epithelial cell lines in vitro
To ascertain the ability of E. coli BM2710/pGB2Oinv-hly to invade and transfer genetic material to colonic epithelial cells, CMT-93 monolayers were incubated with E. coli BM2710/pGB2Oinv-hly carrying either pEGFP-C1 or pUC18Ogfpmut1 for 2 h at MOI 50 or 100. E. coli BM2710/pGB2Oinv-hly invaded nearly 95% of epithelial cells (data not shown), whereas 1.4% (at MOI 50) and 2.1% (at MOI 100) of cells expressed EGFP after 48 h of culture, as determined by FACS analysis. Thus, engineered invasive bacteria would successfully invade and deliver the transgene to mouse colonic epithelial cells in vitro. Of note, lipofection with 1 mg of purified pEGFP-C1 DNA of CMT-93 resulted in 33.9% GFP-positive cells.
We then tested if E. coli BM2710/pGB2Oinv-hly could deliver a functional therapeutic gene such as TGF-b1 to colonic epithelial cells. RT-polymerase chain reaction (PCR) yielded a 320-bp fragment, corresponding to a vector-specific mRNA transcript in CMT-93 monolayers incubated with E. coli BM2710/pGB2Oinv-hly, but not with E. coli BM2710/pGB2, both harboring plasmid pC1OTGF-b1 (Figure 1a) . Quantitative RT-PCR showed the presence of plasmid-specific transcripts in CMT-93 cells following 24 and 48 h of incubation with invasive E. coli BM2710/pGB2Oinv-hly (12.370.7 and 15.171.1 of TGF-b1 mRNA/mg total RNA, respectively) but not with BM2710/pGB2.
Following incubation of E. coli BM2710/pGB2Oinv-hly+pC1OTGF-b1, CMT-93 cells released a significant amount of TGF-b1 in the culture medium. As shown in Figure 1b , the TGF-b1 content of the culture medium peaked at 48 h and then slightly decreased. We could not detect any significant increase in TGF-b1 in the conditioned medium of CMT-93 cells preincubated with either E. coli BM2710/pGB2Oinv-hly+pC1 or BM2710/ pGB2+pC1OTGF-b1 (Figure 1b ).
Oral administration of E. coli BM2710/pGB2Oinv-hly carrying pC1OTGF-b1 reduces the severity of 2,4-dinitrobenzene sulfonic acid (DNBS)-induced colitis
We have determined the therapeutic effect on DNBS colitis of the TGF-b1 gene delivered to the colonic mucosa by E. coli BM2710/pGB2Oinv-hly. Rectal administration of DNBS-induced colitis, characterized by a major body weight loss, increased colonic myeloperoxidase (MPO) activity, macroscopic and microscopic mucosal damage (Figures 2 and 3 ). Colitis severity was significantly reduced by a single oral administration of 10 8 CFU of E. coli BM2710/pGB2Oinv-hly+pC1OTGF-b1 ( Figure 2 ). Thus, mice receiving the therapeutic gene via nonpathogenic enteric bacteria showed only a transient weight loss, a modest macroscopic colonic damage, and slight increase in MPO activity as compared to the nontreated mice or animals dosed with E. coli BM2710/ pGB2Oinv-hly+pC1 ( Figure 2 ). Histologic evaluation of mice treated with E. coli BM2710/pGB2Oinv-hly+ pC1OTGF-b1 showed that the severity of the inflammatory infiltrate and the mucosal damage were drastically reduced ( Figure 4) . Surprisingly, as shown in Figures 2  and 3 , the severity of DNBS colitis was also significantly reduced in animals treated with noninvasive E. coli BM2710/pGB2 harboring pC1OTGF-b1.
Effect of colitis on tissue distribution of pC1OTGF-b1-specific transcripts
It is known that during colitis nonspecific bacterial translocation across the mucosa can occur through ulcers Engineered E. coli delivers genes to the colonic mucosa I Castagliuolo et al that disrupt the integrity of the epithelial barrier. 20 Therefore, we investigated if during colitis the distribution the therapeutic gene delivered by the bacterial vector was altered. As shown in Figure 4 , following administration to normal mice of invasive E. coli BM2710/pGB2Oinv-hly, but not a noninvasive E. coli BM2710/pGB2, plasmid-specific transcripts were detectable only in the intestinal mucosa. By contrast, following administration of invasive or noninvasive BM2710 to colitic mice, plasmid-specific transcripts were detectable in the colonic mucosa and also in the spleen, liver, and the lungs, suggesting that gene delivery to extracolonic districts occurred as a consequence of bacterial leakage through the damaged mucosal barrier (Figure 4 ). However, no viable E. coli BM2710/pGB2Oinv-hly or BM2710/ pGB2 could be recovered from these tissues of either normal or colitic animals in the same experiments. These data therefore suggest that invasive and noninvasive E. coli BM2710 translocate across the mucosa but, since they are dap auxotroph, they lyse in animal's tissues because of impaired cell wall synthesis 13 and can transfer functional genetic information to the host cells.
An inflammation-inducible promoter modifies the expression of vector-specific transcripts
Since disruption of mucosal integrity during colitis caused a widespread distribution of the therapeutic gene, we placed the TGF-b1 gene under the control of an eukaryotic-inducible promoter. The constitutive early CMV promoter in the pC1OTGF-b1 was replaced by a nucleotide sequence corresponding to the human IL-8 promoter region (À955, +5 bp). This sequence is able to drive transcription of the structural genes in cells exposed to an inflammatory milieu.
21,22
After incubation of E. coli BM2710/pGB2Oinv-hly+ pC1OTGF-b1 IND with CMT-93 ( Figure 5 ) or a human colonic epithelial cell line (HT-29, data not shown), plasmid-specific transcripts were detectable following monolayers exposure to proinflammatory cytokines such as rIL-1b or rTNFa, but not in nonstimulated cells. As expected, CMT-93 cells incubated with E. coli BM2710/ pGB2Oinv-hly+pC1OTGF-b1 IND released a significant amount of TGF-b1 in the culture medium following exposure to rIL-10 or rTNFa, but not in basal, nonstimulated conditions ( Figure 5 ).
Since the inducible promoter effectively drove expression of the therapeutic gene in a mouse cell line following exposure to inflammatory cytokines, we tested the effect of the inflammation-inducible promoter on tissue distribution during colitis. As shown in Figure 6 , oral administration of E. coli BM2710/pGB2Oinv-hly+ pC1OTGF-b1 IND led to the expression of the transgene mainly in the inflamed colonic mucosa, as opposed to mice receiving the therapeutic gene under the control of the constitutive early genes CMV promoter (compare Figures 4 and 6 ).
Effect of the oral administration of E. coli BM2710/ pGB2Oinv-hly harboring the inflammation-inducible pC1OTGF-b1 IND on DNBS colitis
As shown in Figure 7 , following oral administration to mice of E. coli BM2710/pGB2Oinv-hly+pC1OTGF-b1 IND , the therapeutic effects on DNBS colitis were comparable to those in animals treated with E. coli BM2710/ pGB2Oinv-hly+pC1OTGF-b1. Thus, colitis-induced body weight loss increased mucosal MPO activity, and microscopic and macroscopic damage were significantly reduced in mice treated with a single administration of E. coli BM2710/pGB2Oinv-hly+pC1OTGF-b1 IND driving TGF-b1 synthesis mainly in the inflamed intestinal mucosa (Figures 6 and 7 ).
Discussion
Administration of recombinant immunomodulant molecules to normalize Th1/Th2 cytokine production within the colonic mucosa of IBD patients is a tempting therapeutic strategy. 1, 23 . However, cytokines administered through systemic routes are readily cleared and their mucosal bioavailability is quite limited. 1 Thus, although low doses of immunomodulant cytokines, such as rIL-10 in Crohn's disease, are relatively safe they are barely effective, whereas higher doses are associated with severe systemic side effects. 24 , 25 An attractive Engineered E. coli delivers genes to the colonic mucosa I Castagliuolo et al alternative to exogenous administration of recombinant cytokines is the transfer of genetic information to obtain in vivo targeted production of therapeutic molecules.
In an effort to develop a safer and more efficient strategy to deliver genes encoding immunoregulatory proteins to the intestinal mucosa, we have taken advantage of nonpathogenic enteric bacteria as vectors.
Live bacteria are emerging as a safe, powerful, and versatile tool for a variety of applications. To date, it is well accepted that dietary supplementation with Lactobacillus spp. or nonpathogenic E. coli significantly reduce the severity of spontaneous or chemically induced colitis in animals and is effective in the maintenance treatment of patients with UC or chronic relapsing pouchitis. 26, 27, 28 In addition, bacteria can be genetically manipulated either to express surface proteins or to release cytokines to modulate the activity of the mucosal immune system. Thus, E. coli, Salmonella and Shigella spp. expressing surface recombinant peptide antigens stimulate specific immune responses, 29, 30 whereas rIL-10 released by Lactococcus lacti prevented the onset of colitis in experimental animal models. 31 Bacteria can be used to deliver DNA to eukaryotic cells. Attenuated mutant strains of Shigella flexneri, Salmonella typhimurium as well as invasive E. coli and L. monocytogenes can successfully transfer in vitro plasmid DNA to a wide range of rodents and primate cell lines as well as dendritic cells. [12] [13] [14] [15] [16] So far, the ability of Shigella and Salmonella to target dendritic cells has been mainly exploited to develop DNA vaccines. 12, 15, 32 However, more recently, invasive bacteria have been used also as DNA vectors to correct inherited genetic defects in somatic cells. Administration to genetically immunodeficient mice of avirulent Salmonella bearing murine IFN-g gene resulted in transgene expression within macrophages and dendritic cells, correction of the genetic defect, and restoration of the cellular phenotype. 32, 33 Invasive bacteria can efficiently transfer genes into nondividing differentiated cells, including normal epithelial cells layering the intestinal mucosa, thus offering an alternative to viral vectors.
Enteric-bacteria-based gene delivery systems possess several advantages over currently available viral vectors for transfer of genetic material to mucosal cells. 34 Taking advantage of the intestinal tropism of E. coli BM2710/ pGB2Oinv-hly, the TGF-b1 transgene was expressed only in the intestinal mucosa following administration to healthy animals ( Figure 4 ). Therefore, it was not surprising to obtain a striking reduction of the DNBSinduced inflammatory damage in the colonic mucosa after administration of 10 8 bacteria, which correspond to the delivery of less than 50 ng of plasmid DNA. Using lymphocytes specifically homing to the colonic mucosa, we were able to use over 10-fold less genetically manipulated cells than splenocytes devoid of tissuehoming specificity. 35 In addition, the well-known proinflammatory effects of certain viral vectors and liposomemediated nonviral gene transfer systems can exacerbate pre-existing inflammatory processes or induce systemic inflammatory responses, which may worsen an underlying inflammatory disorder. 36, 37 As expected, administration of E. coli BM2710/pGB2Oinv-hly by oral gavage to mice was quite safe since it did not induce any significant proinflammatory effect in the gastrointestinal mucosa of normal mice, as ascertained by histologic examination and quantification of mucosal MPO and IL-1b levels (data not shown).
It remains unclear how plasmid DNA delivered by means of invasive bacteria is transported from the phagolysosome into the nucleus of the host cell. 10, 11 Studies with Listeria mutants defective in escape from the primary vacuole or in intracellular mobility as well as Effect of an inflammation-inducible promoter on plasmid-specific gene expression. CMT-93 cells were incubated for 2 h with E. coli BM2710/pGB2Oinv-hly carrying either plasmid pC1OTGF-b1 or pC1OTGF-b1 IND . Monolayers were then washed and cultured in complete medium for 48 additional hours. Where specified, rIL-1b (10 ng/ml), rTNFa (10 ng/ml), or LPS (10 mg/ml), was added to the culture medium.
(a) RT-PCR was performed on total RNA extracted from monolayers to identify GAPDH and plasmid-specific TGF-b1 transcripts. 
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E. coli BM2710/p GB2Ωinv-hly Figure 6 Effect of an inflammation-inducible promoter on plasmid-specific mRNA transcripts in normal and DNBS-treated animals. Mice (n ¼ 3 per experimental group) were injected intrarectally with either DNBS (100 mg/kg) or only DNBS vehicle and then animals received 10 8 E. coli BM2710/pGB2Oinv-hly carrying pC1OTGF-b1 IND by oral gavage. After 48 h, the animals were killed, total RNA was extracted from colon, liver, spleen, ileum, and the lungs and plasmid-specific TGF-b1 transcripts were quantified by RT-PCR and the values normalized to mGAPDH as the endogenous RNA control. For each condition, four determinations were performed and values are expressed as means7s.e. Engineered E. coli delivers genes to the colonic mucosa I Castagliuolo et al mucosal epithelial cells, confirming that engineered bacteria are effective in transferring somatic genes to nonphagocytic cells (Figures 1, 2 and 4) . Furthermore, E. coli BM2710/pGB2Oinv-hly has recently been used to mediate in situ proteins delivery in tumor implanted in mice and the functional protein resulted in therapeutic benefits, when associated with systemic prodrugs delivery. 40 Although we did not directly characterize the cell population(s) expressing the transgene in vivo in normal animals, E. coli BM2710/pGB2Oinv-hly clearly invaded and remained confined to the mucosal epithelial layer driving the expression of the transgene throughout the gastrointestinal tract (Figure 4) . However during colitis, taking into account the widespread distribution of plasmid-specific transcripts, it is possible that E. coli BM2710/pGB2Oinv-hly transferred the therapeutic gene to different cell populations (eg, phagocytic and endothelial cells) in extra-intestinal districts such as liver and lung, Figure 4) .
The attempt to restrict expression of the therapeutic gene within a tissue of interest aims at reducing systemic toxicity due to expression of toxic genes in normal tissues. Delivery of a therapeutic gene to the target tissue has been pursued either by direct local injection or infusion (physical targeting) or through specific ligand/ receptor interaction (physiological targeting). 41, 42 An alternative approach takes advantage of specific tissue tropism of certain cell populations. Accordingly, genetically modified naive dendritic cells, glomerular mesangial cells, and T cells have been tested to deliver genes encoding anti-inflammatory cytokines. [43] [44] [45] In addition, it is possible to control expression of the transgene at the transcriptional level, since regulation of transcription results from the binding of specific proteins to DNA enhancer/promoters. 46 Either tissue-specific or tumorspecific promoters have been widely tested to develop safer and more efficient gene therapy. 46, 47 Our initial strategy to improve tissue targeting was based on the proximity of the colonic mucosa to the luminal bacteria. However, loss of integrity of the mucosa during an inflammatory process results in bacterial translocation across the mucosa, 20, 48 leading to widespread distribution of the transgene (Figure 4) . We took advantage of upregulation of CXC chemokine expression in cells exposed to inflammatory cytokines through activation of specific intracellular signal pathways. 21, 22, 49 Replacement in plasmid C1OTGF-b1 of the constitutive CMV promoter by the hIL-8 promoter allowed to switch-on the transcription of the transgene either in vitro in epithelial cells exposed to an inflammatory milieu (ie IL-1b and TNF-a, Figure 5 ) and in vivo in inflamed tissues ( Figure  6 ). This restricted expression of the therapeutic gene to the tissue involved in an inflammatory process.
Introduction in clinical setting of gene therapy will be dictated by the possibility of spatial and temporal control of therapeutic gene expression. We report the use of a nonpathogenic strain, E. coli BM2710/pGB2Oinv-hly, as a delivery vector for transient gene therapy of intestinal disorders. In the presence of an intact intestinal barrier, the E. coli BM2710/pGB2Oinv-hly gene delivery system may represent an attractive tool to treat widespread intestinal genetic disorders involving primarily the enterocytes, such as lactose intolerance or the immune system associated to the intestinal mucosa, such as food allergies. 50, 51 In the presence of a functional deficit of Figure 7 E. coli BM2710/pGB2Oinv-hly plus pC1OTGF-b1 IND decreases inflammation. DNBS colitis was induced as described in Materials and methods and the animals (n ¼ 8 per group) were randomly allocated to receive by oral gavage either BHI vehicle (b), E. coli BM2710/pGB2Oinv-hly carrying plasmid pC1OTGF-b1 (c), E. coli BM2710/pGB2Oinv-hly carrying the plasmid pC1OTGF-b1 IND (d). A group of mice (control, n ¼ 6) were injected rectally with DNBS vehicle only (a). Severity of colitis was monitored by measure of the body weight at the moment of DNBS injection (T0), after 3 (T1) and 5 (T2) days (A). At the end of the experiment, animals were killed, the whole colon was removed, flat opened, washed in ice cold saline and a macroscopic damage score (0-10) was assigned by two independent investigators (B), whereas MPO activity, expressed as U/mg of wet tissue (C) was determined on full-thickness colonic samples. Results are presented are means7s.e. and **denotes Po0.01 versus control, *Po0.05 versus control and + denotes Po0.01 versus DNBS. Engineered E. coli delivers genes to the colonic mucosa I Castagliuolo et al the mucosal barrier and to limit the expression of the therapeutic transgene within the inflamed tissues, an inducible regulatory promoter should be used. It is possible that in the near future, using appropriate disease-induced specific genes, one may be able to restrict even more tightly the expression of the therapeutic gene to the affected district.
Materials and methods

Bacterial strains and plasmids
Plasmids pGB2 and pGB2Oinv-hly 14 were introduced by trasformation into E. coli BM2710 auxotroph for diaminopimelic acid. 13 Plasmid pC1OTGF-b1 (kindly provided by G Prud'Homme, McGill University, Canada) encodes the full-length mouse TGF-b1 under the control of the early genes promoter of CMV. Plasmid pC1OTGF-b1 IND was obtained by removal from pC1OTGF-b1 the CMV promoter by BglII/XhoI digestion followed by insertion of a 950-bp sequence corresponding to the hIL-8 promoter region (À945, +5 bp) amplified from human genomic DNA. Recombinant plasmids were sequenced and DNA purified by double CsCl 2 -ethidium bromide ultracentrifugation.
Delivery of functional genes to intestinal epithelial cells in vitro
The mouse MCT-93 (purchased from European Collection of Cell Culture, UK) intestinal epithelial cell line was cultured in DMEM containing 10% heat-inactivated FBS and 1% penicillin/streptomycin solution. When required, cells were trypsinized and seeded at 2-5 Â 10 5 ml in six-well plates for 24 h before incubation with E. coli BM2710/pGB2Oinv-hly or BM2710/pGB2. The E. coli strains were grown overnight at 361C with shaking in brain heart infusion broth (BHI, Difco Laboratories Detroit, MI, USA) supplemented with 0.5 mM dap (Sigma, St Louis, MO, USA), 25 mg/ml of streptomycin, 100 mg/ml of ampicillin, and 25 mg/ml of kanamycin when required.
14 Bacteria were harvested by centrifugation in the late logarithmic phase of growth (OD 260 of approximately 4) resuspended in DMEM containing 0.5 mM dap and 10% FCS at 10 9 bacteria/ml and then added, at multiplicity of infections (MOI) ranging from 1:1 to 1:100 to intestinal epithelial cell monolayers. The plates were incubated for 2 h at 371C, then cells were washed three times with DMEM and incubated for additional 24-72 h in complete medium containing 20 mg/ml of gentamicin. When indicated, 10 ng/ml of rIL-1b or rTNF-a (Biosource, CA, USA) were added to the culture medium.
To assess EGFP expression in MCT-93 cells, 48 h after incubation of monolayers with E. coli BM2710/ pGB2Oinv-hly or BM2710/pGB2 containing or not pEGFP-C1, the cells were trypsinized, washed twice with 2% FCS in phosphate-buffered saline (PBS), resuspended in the same buffer at 10 6 cell/ml and 3 Â 10 4 cells were analyzed using a FACS Scan cytometer with Cell Quest software (Becton-Dickinson, Mountain View, CA, USA). 14 To determine expression of plasmid-coded TGF-b1, conditioned culture media was collected, centrifuged (1000 g for 10 min) and the supernatants were assayed for TGF-b1 content by ELISA. Total RNA was extracted from the cellular monolayers to quantify plasmidspecific TGF-b1 mRNA transcripts.
In vivo studies and tissue analyses
Procedures involving animal studies were carried out following the guidelines of the Institutional Animal Care and Use Committee of the University of Padua. Male Balb/c mice (20-22 g, n ¼ 6-8 per group) were anesthetized by i.p. injection of ketamine hydrochloride (900 mg/g body weight) and xylazine hydrochloride (20 mg/g body weight) and colitis was induced by intrarectal instillation of 100 ml of a DNBS solution (40 mg/ml in 40% ethanol) as described. 52 At the time of DNBS administration, mice were randomly allocated to receive by oral gavage 10 8 CFU (total volume 100 ml) of either invasive E. coli BM2710/pGB2Oinv-hly or noninvasive BM2710pGB2 harboring one of the following plasmids: pC1, pC1OTGF-b1 or pC1OTGF-b1 IND . A group of mice received the intrarectal instillation of DNBS and received by oral gavage 100 ml BHI (nottreated control). A different group of mice received an intrarectal injection of DNBS vehicle and did not receive further treatment (noncolitic control). After 5 days, the animals were killed and the tissues harvested. The whole colon was removed, flat opened, rinsed in ice-cold PBS, and a macroscopic damage score (0-10) was assigned by two independent investigators, unaware of the treatment administered to each mouse, as an index of disease activity. 52 Each colon was then divided in two longitudinally: one part was fixed in 4% paraformaldehyde (PFA) for subsequent histological examination, 52 and the other was snap frozen in liquid nitrogen and stored at À801C to assess MPO, as a marker of leukocyte infiltration, or to extract total tissue RNAs. 53 
RNA isolation and quantitative real-time RT-PCR analysis
Total RNA was isolated from tissue samples (smashed down using a Polytron tissue homogenizer) or from MCT-93 monolayers by phenol-chloroform extraction as described. 52 Contaminating DNA was removed with RQ-1 RNase-free DNase (Promega) and random primed cDNAs were generated using MuLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). PCR was performed for mouse GAPDH (housekeeping Engineered E. coli delivers genes to the colonic mucosa I Castagliuolo et al control gene) and vector-specific TGF-b1 transcripts as summarized in Table 1 . Amplification products were separated on 1.5% agarose gels and visualized by ethidium bromide staining using an U.V. transilluminator. Real-time quantitative RT-PCR analysis was performed on an ABI Prism 7700 Sequence Detector (Applied biosystems). For each sample, the amount of target and endogenous reference was extrapolated from a standard curve prepared using serially diluted corresponding cDNAs subcloned into pGEM-T vector (Promega). The amplified fragments were sequenced by automated sequencing. 54 
TGF-b1 ELISA
Active TGF-b1 was measured in conditioned medium of cultured CMT-93 monolayers using a commercially available ELISA kit (Promega). To determine total TGFb1 levels, latent TGF-b1 was converted to the active form by sample acidification (pH 2) with 1 M HCl for 15 min, followed by NaOH neutralization. Optical densities were measured using an ELISA plate-reader (LX300 Epson Diagnostic) at a wavelength of 490 nm. TGF-b1 levels were expressed as ng/ml.
Culture of E. coli BM2710 from tissues
Following oral administration of either E. coli BM2710/ pGB2Oinv-hly or E. coli BM2710/pGB2 to normal or colitic mice, animals were killed after 2-5 days and blood, liver, spleen, and lungs were collected aseptically. Tissues were homogenized in BHI medium (1:5 w/v ratio) supplemented with 0.5 mM dap and 100 ml of the homogenate were plated on BHI agar plates supplemented with 0.5 mM dap and streptomycin (25 mg/ml). The plates were incubated for 24-48 h at 371C and examined for the presence of colonies.
Statistical analysis
Statistical analysis was performed using the ANOVA and Bonferroni's test. Statistical significance was considered for P-values o0.05.
